LAS VEGAS – CovInnovationsTM, a Las Vegas-based biotech company, is announcing a strategic partnership with Roseman University of Health Sciences for research on COVID-related therapies and treatments, particularly a new medical advance that has shown significant increase in survival rates for late-stage COVID-19 patients requiring hospitalization and oxygen or who have been intubated.
The new drug, CovArrestTM, is composed of two current FDA-approved drugs that work synergistically to attack the same disease and are both metabolized by the same liver enzymes. One of the components showed significant success in a clinical retrospective review completed in December 2020. The study demonstrated a 68 percent reduction in mortality (p<0.05) and a 37 percent reduction in length of hospital stay (p<0.01). The treated group and the control group both received standard of care treatment as of June 2020. Patients in the group provided the drug had a 93.5 percent survival rate as compared to the control group which had a survival rate of 78.5 percent. In order to improve survival rates beyond 93.5%, a second agent was added to the original formulation. CovInnovations is currently in discussions with the FDA to obtain Investigational New Drug Approval and Emergency Use Authorization for CovArrestTM.
CovInnovationsTM recently signed a memorandum of understanding with Roseman University to conduct collaborative research on COVID-19 treatment. “Roseman University has significant research infrastructure, including expert faculty, administrative resources, document acquisition services and research laboratories already operating in southern Nevada,” said Dr. Aury Nagy, founder of CovInnovationsTM. “We anticipate our partnership will dramatically advance our drug development capabilities as we seek FDA approval of viable therapies that have shown potential for saving tens of thousands of lives.”
COVID-19 causes death by inducing a cytokine storm in the lungs which causes acute respiratory distress syndrome, particularly among those with weakened immune systems or long-standing medical conditions. Many of the antiviral drugs recently approved by the FDA are only useful in the first 5-7 days of COVID-19 infections when viral replication is the predominant cause of illness. Once the disease progresses to the over-active inflammatory phase, antivirals have not proven to be very effective. Unlike the antiviral drugs approved so far, CovArrestTM is a late-stage critical care treatment that is believed to suppress the cytokine storm and end viral replication at the cellular level.
”We are excited to partner with CovInnovationsTM in the pursuit of desperately needed COVID therapies,” said Dr. Jeff Talbot, Vice President for Research at Roseman University. “Their innovative technologies and novel approach to drug discovery are vital to help us successfully emerge from the pandemic.”
“With FDA approval, we can immediately launch statistically valid clinical trials and, when approved for production and distribution, be able to deploy treatment options that, if previously available, could have saved up to two-thirds of those who died from COVID,” said Dr. Nagy.
###
ABOUT COVINNOVATIONS
CovInnovationsTM creates technologies and solutions directly related to the COVID-19 pandemic. The company’s patent-pending treatments seek to create a new standard of care in the battle against this disease. CovInnovationsTM products feature groundbreaking technologies that assess, diagnose and treat COVID-19 with the goal of integrating our world back to pre-pandemic times. The company was founded by Dr. Aury Nagy, M.D. FAANS, a neurosurgeon practicing in Las Vegas.
For further information, visit: www.covinnovations.com.
ABOUT ROSEMAN UNIVERSITY
Founded in Henderson, Nevada in 1999, Roseman University of Health Sciences is a non-profit, private institution of higher learning training the next generation of undergraduate and graduate-level health care professionals that serve, collaborate and set new standards in their communities and within their professions. With campuses in Henderson and Summerlin (Las Vegas), Nevada and South Jordan, Utah, the University is comprised of the College of Dental Medicine, offering an Advanced Education in Orthodontics and Dentofacial Orthopedics/MBA residency and Doctor of Dental Medicine program; College of Pharmacy, offering a Doctor of Pharmacy; College of Nursing, offering an Accelerated Bachelor of Science in Nursing and Master of Science in Nursing/Family Nurse Practitioner; and College of Graduate Studies offering a Master of Science in Pharmaceutical Sciences and Master of Science in Biomedical Sciences. Roseman University of Health Sciences will also offer a Doctor of Medicine through its College of Medicine, once it becomes accredited. More than 7,000 Roseman graduates are caring for patients, conducting research, and engaged in public health and policy in Nevada, Utah, and across the country. Roseman University is regionally accredited by the Northwest Commission on Colleges and Universities.
For further information, visit: www.roseman.edu
FORWARD LOOKING STATEMENT: Various statements contained in this presentation, including those that express a belief, expectation or intention, as well as those that are not statements of historical fact, are forward-looking statements. These forward-looking statements may include projections and estimates concerning the timing and success of strategies, plans or intentions. We have based these forward-looking statements on our current expectations and assumptions about future events. These assumptions include, among others, our projections and expectations regarding: market trends litigation, our ability to create an opportunity with attractive current yields and upside. While we consider these expectations and assumptions to be somewhat reasonable, they are inherently subject to significant business, economic, competitive, regulatory and other risks, contingencies and uncertainties, most of which are difficult to predict and many of which are beyond our control and could cause actual results to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Investors should not place undue reliance on these forward-looking statements. We undertake no obligation to update any forward-looking statements to conform to actual results or changes in our expectations, unless required by applicable law.
# # #
